Founded in 2019 and headquartered in San Francisco, Aditum Bio targets clinic-ready therapies to help underserved patient populations. It acquires assets from biotech and pharma companies and develops them through Phase II, utilizing TrialSpark as the clinical research engine. Aditum Bio's mission is to rapidly translate scientific discoveries into innovative new medicines, forming companies and staffing them with medical and scientific experts. The firm was launched by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, and currently manages a broad portfolio of clinical stage companies.